| scholarly article | Q13442814 |
| P50 | author | Hans-Jürgen Wester | Q128303541 |
| Carlos Mas-Moruno | Q38323013 | ||
| Elisabetta A Cavalcanti-Adam | Q40380112 | ||
| P2093 | author name string | Horst Kessler | |
| Benjamin Geiger | |||
| Ute Reuning | |||
| Florian Rechenmacher | |||
| Stefanie Neubauer | |||
| Oleg V Maltsev | |||
| Joachim Spatz | |||
| Johannes Notni | |||
| Tobias G Kapp | |||
| Revital Zarka | |||
| P2860 | cites work | Crystal structure of the extracellular segment of integrin alpha Vbeta3 | Q24291661 |
| Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand | Q24292425 | ||
| Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD | Q24805375 | ||
| Integrin-based therapeutics: biological basis, clinical use and new drugs | Q26773026 | ||
| Solution structures and integrin binding activities of an RGD peptide with two isomers | Q27631496 | ||
| Structure of a Complete Integrin Ectodomain in a Physiologic Resting State and Activation and Deactivation by Applied Forces | Q27653293 | ||
| Crystal structure of α5β1 integrin ectodomain: Atomic details of the fibronectin receptor | Q27678221 | ||
| Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins | Q28202564 | ||
| Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors | Q28236317 | ||
| Force fluctuations within focal adhesions mediate ECM-rigidity sensing to guide directed cell migration | Q28508256 | ||
| Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors | Q28645681 | ||
| Integrins in cancer: biological implications and therapeutic opportunities | Q29614536 | ||
| Environmental sensing through focal adhesions | Q29615211 | ||
| Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule | Q29616413 | ||
| Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels | Q29619679 | ||
| N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists | Q30580638 | ||
| Solution stability of linear vs. cyclic RGD peptides | Q30744942 | ||
| Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells | Q31087982 | ||
| Definition of an unexpected ligand recognition motif for alphav beta6 integrin | Q31932925 | ||
| Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins | Q32060527 | ||
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial | Q33417361 | ||
| A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors | Q33616878 | ||
| Ligand binding to integrins | Q33912940 | ||
| Endothelial alpha5 and alphav integrins cooperate in remodeling of the vasculature during development | Q33929646 | ||
| Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation. | Q34030885 | ||
| The extracellular matrix at a glance | Q34152843 | ||
| RGD modified polymers: biomaterials for stimulated cell adhesion and beyond | Q34223126 | ||
| Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members | Q34504056 | ||
| Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids | Q34567390 | ||
| The glycophorin A transmembrane sequence within integrin αvβ3 creates a non-signaling integrin with low basal affinity that is strongly adhesive under force | Q34751810 | ||
| Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity | Q35127140 | ||
| Therapeutic antagonists and conformational regulation of integrin function | Q35209992 | ||
| Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium | Q35218871 | ||
| PET Imaging of Integrin Positive Tumors Using F Labeled Knottin Peptides | Q35641937 | ||
| Overview of the matrisome--an inventory of extracellular matrix constituents and functions | Q35645897 | ||
| Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation | Q35701298 | ||
| Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study | Q35788615 | ||
| A cell surface receptor complex for collagen type I recognizes the Arg-Gly-Asp sequence | Q36216437 | ||
| Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting | Q36570185 | ||
| Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain | Q36729317 | ||
| The integrins | Q36837362 | ||
| Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers | Q36952035 | ||
| RGDN peptide interaction with endothelial alpha5beta1 integrin causes sustained endothelin-dependent vasoconstriction of rat skeletal muscle arterioles | Q37372789 | ||
| The role of thiols and disulfides on protein stability. | Q37524089 | ||
| Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing | Q37675931 | ||
| Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides | Q37694643 | ||
| Integrins as therapeutic targets: lessons and opportunities | Q37795552 | ||
| Integrins as therapeutic targets. | Q38013361 | ||
| Tumor Targeting via Integrin Ligands | Q38134759 | ||
| Integrin modulators: a patent review | Q38139612 | ||
| Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. | Q38191051 | ||
| Stable Peptides Instead of Stapled Peptides: Highly Potent αvβ6-Selective Integrin Ligands | Q38811936 | ||
| αvβ3- or α5β1-Integrin-Selective Peptidomimetics for Surface Coating | Q38852942 | ||
| Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides | Q38933771 | ||
| Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical | Q38947780 | ||
| Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). | Q39011647 | ||
| Functionalizing αvβ3- or α5β1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro | Q39205680 | ||
| The RGD motif in fibronectin is essential for development but dispensable for fibril assembly | Q39743726 | ||
| Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells | Q40147550 | ||
| Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands | Q40179951 | ||
| Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. | Q40201435 | ||
| Interface Immobilization Chemistry of cRGD-based Peptides Regulates Integrin Mediated Cell Adhesion | Q41157466 | ||
| Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins alpha IIb beta 3, alpha V beta 3 and alpha 5 beta 1 and in cell adhesion inhibition | Q41425538 | ||
| Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans | Q41434182 | ||
| Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent | Q42282530 | ||
| Influence of length and flexibility of spacers on the binding affinity of divalent ligands | Q42522246 | ||
| Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients | Q43788666 | ||
| Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice | Q44313688 | ||
| Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design | Q44604117 | ||
| Activation of integrin function by nanopatterned adhesive interfaces | Q44832858 | ||
| A molecular toolkit for the functionalization of titanium-based biomaterials that selectively control integrin-mediated cell adhesion | Q44965368 | ||
| Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138. | Q45226958 | ||
| Spontaneous formation of L-isoaspartate and gain of function in fibronectin. | Q45862901 | ||
| Ligands for mapping alphavbeta3-integrin expression in vivo. | Q45986254 | ||
| Breaking the dogma of the metal-coordinating carboxylate group in integrin ligands: introducing hydroxamic acids to the MIDAS to tune potency and selectivity | Q46062883 | ||
| Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists | Q46563136 | ||
| Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa | Q46581809 | ||
| Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor | Q46594811 | ||
| Multiple N-methylation by a designed approach enhances receptor selectivity | Q46921733 | ||
| Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides | Q49177235 | ||
| Small Cause, Great Impact: Modification of the Guanidine Group in the RGD Motif Controls Integrin Subtype Selectivity. | Q50902764 | ||
| Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3. | Q53092366 | ||
| Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. | Q53686513 | ||
| Radioligand Binding Assays and Their Analysis | Q56987865 | ||
| Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins | Q57189889 | ||
| Adhesion articulated | Q58057878 | ||
| Receptor-Bound Conformation of Cilengitide Better Represented by Its Solution-State Structure than the Solid-State Structure | Q58855681 | ||
| Conformational Control of Integrin-Subtype Selectivity in isoDGR Peptide Motifs: A Biological Switch | Q58855726 | ||
| Probing Integrin Selectivity: Rational Design of Highly Active and Selective Ligands for the α5β1 and αvβ3 Integrin Receptor | Q58856002 | ||
| Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins | Q61764268 | ||
| 3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl Phenylthiosulfonate: A Thiol-Reactive Agent for the Chemoselective18F-Glycosylation of Peptides | Q64030207 | ||
| Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus | Q67980883 | ||
| Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation | Q76645267 | ||
| NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging | Q79135180 | ||
| Design and synthesis of a new class of selective integrin alpha5beta1 antagonists | Q80578744 | ||
| Selective RGD-Mediated Adhesion of Osteoblasts at Surfaces of Implants | Q88521460 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 39805 | |
| P577 | publication date | 2017-01-11 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins | |
| P478 | volume | 7 |
| Q64065932 | A Dual Molecular Biointerface Combining RGD and KRSR Sequences Improves Osteoblastic Functions by Synergizing Integrin and Cell-Membrane Proteoglycan Binding |
| Q97905035 | A thrombolytic therapy using diagnostic ultrasound combined with RGDS-targeted microbubbles and urokinase in a rabbit model |
| Q90055871 | Biomimetic nanoparticle technology for cardiovascular disease detection and treatment |
| Q36290081 | Canstatin inhibits hypoxia-induced apoptosis through activation of integrin/focal adhesion kinase/Akt signaling pathway in H9c2 cardiomyoblasts |
| Q60305246 | Cell-Matrix Interactions and Matricrine Signaling in the Pathogenesis of Vascular Calcification |
| Q91805012 | Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity |
| Q92661080 | Conjugates of Copper Alginate with Arginine-Glycine-Aspartic Acid (RGD) for Potential Use in Regenerative Medicine |
| Q91643705 | Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery |
| Q64926507 | Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting. |
| Q88970982 | Design of functionalized cyclic peptides through orthogonal click reactions for cell culture and targeting applications |
| Q64055779 | Differential adhesion and fibrinolytic activity of mesenchymal stem cells from human bone marrow, placenta, and Wharton's jelly cultured in a fibrin hydrogel |
| Q54963298 | Effect of Co-presentation of Adhesive Ligands and Short Hyaluronan on Lymphendothelial Cells. |
| Q41670915 | Exploring the Role of RGD-Recognizing Integrins in Cancer |
| Q64934723 | From Snake Venom's Disintegrins and C-Type Lectins to Anti-Platelet Drugs. |
| Q42287023 | Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing |
| Q90548936 | Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [68Ga]Ga-DOTA-E-[c(RGDfK)]2 PET/CT |
| Q90007268 | In vivo imaging of early stages of rheumatoid arthritis by α5β1-integrin-targeted positron emission tomography |
| Q110951933 | Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2 |
| Q59808060 | Integrin targeting of glyphosate and its cell adhesion modulation effects on osteoblastic MC3T3-E1 cells revealed by label-free optical biosensing |
| Q98727151 | Interactions at engineered graft-tissue interfaces: A review |
| Q47107605 | Investigating the Interaction of Cyclic RGD Peptidomimetics with αVβ₆ Integrin by Biochemical and Molecular Docking Studies |
| Q99587442 | Linker Hydrophilicity Modulates the Anticancer Activity of RGD-Cryptophycin Conjugates |
| Q41591759 | Mechanistic basis for the recognition of laminin-511 by α6β1 integrin. |
| Q47328232 | Molecular Tension Probes for Imaging Forces at the Cell Surface. |
| Q38695235 | Multifunctional αvβ6 Integrin-Specific Peptide-Pt(IV) Conjugates for Cancer Cell Targeting |
| Q40098290 | New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology |
| Q55054276 | On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site. |
| Q47600958 | Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3. |
| Q98178368 | Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies |
| Q50673192 | Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis. |
| Q92385408 | Preclinical evaluation of [18F]FB-A20FMDV2 as a selective marker for measuring αVβ6 integrin occupancy using positron emission tomography in rodent lung |
| Q64065341 | Probabilistic variable-length segmentation of protein sequences for discriminative motif discovery (DiMotif) and sequence embedding (ProtVecX) |
| Q58796867 | Recombinant and Chimeric Disintegrins in Preclinical Research |
| Q110951954 | SARS-CoV-2 uses major endothelial integrin αvβ3 to cause vascular dysregulation in-vitro during COVID-19 |
| Q93068998 | Size-Dependent Cellular Uptake of RGD Peptides |
| Q92677533 | Synthesis and Biological Characterization of Monomeric and Tetrameric RGD-Cryptophycin Conjugates |
| Q57973088 | Synthesis and Biological Evaluation of Paclitaxel Conjugates Involving Linkers Cleavable by Lysosomal Enzymes and αV β3 -Integrin Ligands for Tumor Targeting |
| Q92165417 | Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin αV β3 |
| Q92794475 | Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery |
| Q55338721 | Synthesis and biological evaluation of RGD and isoDGR peptidomimetic-α-amanitin conjugates for tumor-targeting. |
| Q47162721 | Targeting Metastasis with Snake Toxins: Molecular Mechanisms |
| Q92372532 | Targeting the Achilles' heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase |
| Q93102446 | The ZT Biopolymer: A Self-Assembling Protein Scaffold for Stem Cell Applications |
| Q90334696 | Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6 |
| Q57975614 | Toward Angiogenesis Inhibitors Based on the Conjugation of Organometallic Platinum(II) Complexes to RGD Peptides |
| Q47128315 | Towards the cell-instructive bactericidal substrate: exploring the combination of nanotopographical features and integrin selective synthetic ligands |
| Q90413951 | Tripeptide Arg-Gly-Asp (RGD) modifies the molecular mechanical properties of the non-muscle myosin IIA in human bone marrow-derived myofibroblasts seeded in a collagen scaffold |
| Q41019174 | Tumor Targeting with an isoDGR-Drug Conjugate |
| Q92287651 | Up-regulated fibronectin in 3D culture facilitates spreading of triple negative breast cancer cells on 2D through integrin β-5 and Src |
| Q93343882 | VANGL2 protein stability is regulated by integrin αv and the extracellular matrix |
Search more.